Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou; Yi‐Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lü; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; L Zhang; Changxuan You

doi:10.1016/s1470-2045(11)70184-x

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou(Tongji University), Yi‐Long Wu(Guangdong General Hospital), Gongyan Chen(Harbin Medical University), Jifeng Feng(Jiangsu Cancer Hospital), Xiao-Qing Liu(Academy of Military Medical Sciences), Changli Wang(Tianjin Medical University Cancer Institute and Hospital), Shucai Zhang(Capital Medical University), Jie Wang(Peking University), Songwen Zhou(Tongji University), Shengxiang Ren(Tongji University), Shun Lü(Shanghai Jiao Tong University), Li Zhang(Sun Yat-sen University), Chengping Hu(Central South University), Chunhong Hu(Central South University), Yi Luo(Hunan Cancer Hospital), Lei Chen(Shantou University), Ming Ye(Shanghai Jiao Tong University), Jianan Huang(Soochow University), Xiuyi Zhi(Capital Medical University), Yiping Zhang(Zhejiang Cancer Hospital), Qingyu Xiu(Second Military Medical University), Jun Ma(Harbin Institute of Petroleum), L Zhang(Sun Yat-sen University), Changxuan You(Nanfang Hospital)

The Lancet Oncology

July 25, 2011

10.1016/s1470-2045(11)70184-x

Cited by 4,094

Abstract

Related Papers

No related papers found

Powered by citation graph analysis